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Insulin-like growth factors inhibit podocyte apoptosis through
the PI3 kinase pathway.
Background. Abnormal podocyte development and progres-
sive podocyte injury have been implicated in a number of human
kidney diseases. Factors necessary for regulating development
and maintenance of this cell type are only beginning to emerge.
Methods. To study the role of the insulin-like growth factor
(IGF) system in regulating podocyte survival, we induced hu-
man fetal podocytes to undergo apoptosis. We demonstrated a
significant increase in apoptosis when these cells were incubated
in the presence of etoposide, as measured by DNA fragmenta-
tion and nuclear membrane condensation and blebbing.
Results. Podocyte apoptosis was reduced to control levels
when the cells were coincubated in the presence of IGF-1. We
showed that the protective effect of IGFs in this cell type was
mediated through the activation of the phosphatidylinositol 3′-
kinase (PI3K) pathway. IGF-1 stimulation resulted in the for-
mation of the insulin receptor substrate (IRS)-1-p85 complex,
an increase in PI3 kinase activity, and activation of protein ki-
nase B (AKT/PKB) and the bcl-2 family member bad. Incuba-
tion of the podocytes with inhibitors of the PI3 kinase pathway
resulted in a loss of this IGF-1 protective effect.
Conclusion. These data demonstrate an important role for
the IGF system in fetal podocyte survival in vitro, and suggest
potential mediators to slow or alleviate the loss or damage of
the podocyte in progressive renal disease.
The dramatic increase in the incidence and prevalence
of chronic kidney disease has resulted in a significant bur-
den for patients, their families and health care providers.
Damage to the podocyte cell layer has been implicated in
the cause of a number of renal abnormalities that often
progress to end-stage renal disease (ESRD) [1, 2]. In ad-
dition, several recent examples of acquired and inherited
kidney diseases [3–6] highlight the importance of normal
podocyte function. These advances demonstrate the im-
portance of the podocyte to normal kidney function, and
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an understanding of the role of the factors necessary for
regulating the development and maintenance of this cell
is beginning to emerge.
The insulin-like growth factors (IGFs) are soluble
peptides that regulate a number of biologic processes,
including cell proliferation, cell differentiation, and cell
survival. Members of the IGF family also have estab-
lished roles in the development and maturation of the kid-
ney [7, 8], including the podocyte [9]. In addition, IGF-1
and IGF-1 receptor (IGF-1R)–deficient mice demon-
strate smaller and fewer glomeruli suggesting the pos-
sibility IGFs and IGF signaling may regulate podocyte
survival [10]. Both IGF-1 and IGF-2 elicit their bio-
logic responses by activating the tyrosine kinase IGF-1R.
Activation of this receptor has been shown to deliver
an antiapoptotic signal through the activation of the
phosphatidylinositol 3′-kinase pathway (PI3K) and sub-
sequent activation of the b-cell lymphoma (bcl-2) family
of pro- and antiapoptotic proteins [11–13].
Apoptosis is a tightly-regulated cellular process that
occurs in the development of several organs and is in-
volved in maintaining normal cell and tissue homeosta-
sis [14]. In the developing kidney, apoptosis results in
the deletion of specific nonterminally differentiated cell
populations while other differentiated cell populations,
including the podocyte, demonstrate minimal apoptosis
and appear to be preferentially protected from cell death
[15, 16]. Growth factor–induced cell signaling and activa-
tion of members of the bcl-2 gene family are important
regulators of apoptosis in several cell models, including
the kidney [17], and may be important in the development
and maintenance of the podocyte.
In this study, we have demonstrated that human fetal
podocytes are protected from apoptosis with IGF stimu-
lation. This protective effect is mediated through stimu-
lation of the IGF-1R, activation of the PI3K pathway, and
the antiapoptotic protein bad. These results demonstrate
a role for IGFs in the survival and maintenance of the
podocyte in vitro, and suggest a potential target pathway
to limit the loss of the podocyte and potentially prevent
or slow the progression of renal disease.
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METHODS
Podocyte isolation
Human fetal glomerular epithelial cells were isolated
and characterized as previously described [9]. This in-
cluded immunoreactivity utilizing a monoclonal antibody
to synaptopodin (monoclonal antibody 6010S) (Maine
Biotechnology, ME, USA) (Fig. 1A). As well, using the
monoclonal antibody 48E11, which recognizes the extra-
cellular domain of nephrin (fibronectin type III–like mo-
tif) (courtesy of Dr. V. Ruotsalainen), the cell monolayers
were shown to express nephrin by Western blot analysis
(Fig. 1B). Briefly, a pure preparation of glomerular cores
was obtained using differential sieving. The glomeru-
lar cores were collected in Iscove’s modified Dulbecco’s
medium (IMDM) cell culture media, and then plated
on 25 cm2 culture flasks in IMDM supplemented with
10% vol/vol fetal calf serum (FCS) (Gibco, Burlington,
Ontario, Canada), penicillin 100 U/mL, and streptomycin
100 U/mL (Gibco). Cells used for experimentation were
plated in IMDM supplemented with 10% fetal bovine
serum (FBS) for 24 hours. The media was removed and
cells were incubated in 1% FBS with antibiotics to allow
the cells to exit the cell cycle and differentiate. All ex-
periments were performed between passages 2 and 5, as
phenotypic changes and an inability to maintain viability
were observed after passage 6. For the apoptosis assays,
the cells were washed with phosphate-buffered saline
(PBS), and media was added with or without serum,
etoposide or IGFs, and in the presence or absence of
LY294002 (1 lmol/L) or Wortmannin (1 lmol/L). For
Western blot analysis, cells were incubated in serum-free
media for 6 hours and then stimulated in the presence or
absence of IGF, with or without PI3K inhibitors for the
indicated time points.
Apoptosis by nuclear morphology
Apoptosis was determined using two distinct apop-
totic markers: DNA fragmentation and changes in nu-
clear morphology. Cultured podocytes were induced to
undergo apoptosis using etoposide (200 lmol/L) in the
presence or absence of IGF-1 (200 ng/mL). Control cells
remained in 1% FBS. At the designated time points,
Hoechst 33258 (Sigma Chemical Co., St. Louis, MO,
USA) and propidium iodide were added to the media,
the cells were fixed with 4% paraformaldehyde and exam-
ined by fluorescence microscopy. Apoptotic nuclei were
identified as small densely staining, fragmented nuclei
that lie slightly above the plane of the monolayer [18,
19], while healthy cells had large, faintly staining nu-
clei with prominent nucleoli. Each treatment was per-
formed four times, and apoptotic nuclei and total nuclei
were counted in five randomly selected fields for each
treatment.
Terminal deoxytransferase (TdT) uridine triphosphate
(UTP) nick end-labeling (TUNEL) assay
Detection of DNA fragmentation was performed using
the fluorescein apoptosis detection system as described in
the manufacturer’s instructions (Promega, Madison, WI,
USA).
Phospholipid extraction and thin-layer chromatography
Phospholipid extraction and thin-layer chromatogra-
phy were performed as previously described [20]. Briefly,
subconfluent fetal podocyte monolayers were incubated
in serum-free media containing radioactive precursors
(ortho [32Pi]PO3- or [3-methyl choline]) for 24 hours
(pulse label period). Media were then removed, and
cells were washed with PBS. Cells were then exposed to
serum free-media containing IGF-1 at 200 ng/mL and
reactions were stopped with 10% trichloroacetic acid
(TCA). Lipids were extracted, separated by thin-layer
chromatography, and visualized by autoradiography. In-
dividual lipid bands were scraped from the plate, and
radioactive counts were determined using a Beckman
LS6500 scintillation counter (Beckman Coulter Canada,
Mississauga, Ontario, Canada). Results were expressed
as means of specific activity.
Immunoprecipitation
Subconfluent monolayers were incubated in serum-
free media for 6 hours and stimulated with IGF-1.
Cells were then washed in cold PBS, and lysed using
0.5 mL of cold immunoprecipitation buffer [1% Tri-
ton X-100, 150 mmol/L NaCl, 10 mmol/L Tris, pH 7.4,
1 mmol/L ethylenediaminetetraacetic acid (EDTA), pH
8.0, 0.2 mmol/L sodium orthovanadate, 1 mmol/L phenyl-
methylsulfonyl fluoride (PMSF), and 0.5% Nonidet
P-40)]. The lysate was centrifuged at 15,000 × g for
15 minutes and the supernatant incubated with 1 to 5 lg of
primary polyclonal insulin receptor substrate-1 (IRS-1)
or PI3K p85 subunit antibodies (Upstate Biotechnology,
Waltham, MA, USA) in 1 × immunoprecitation buffer
for 2 hours with agitation at 4◦C. Protein A sepharose
beads were added for 2 hours or overnight at 4◦C to
capture the immunocomplex. The beads were collected
by pulse centrifugation, washed with immunoprecipita-
tion buffer, and resuspended in 2 × electrophoresis sam-
ple buffer. The complex was eluted from the beads by
boiling the mixture, and samples were then separated by
sodium dodecyl sulfate-polyacrylamide gel electrophore-
sis (SDS-PAGE). The proteins were then transferred and
Western blot analysis performed using antibodies to ei-
ther p85 PI3K or IRS-1 as described below.
Western blot analysis
Western blot analysis was performed as previously
described [9]. Cell monolayers were washed with PBS
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and protein extracted. Samples were separated by SDS-
PAGE and transferred to Immobilon-P polyvinlydine di-
fluoride (PVDF) membranes (Millipore, Bedford, MA,
USA). Nonspecific binding sites were blocked as per
the manufacturer’s instructions, and blots were probed
overnight at 4◦C with specific antibodies to serine
473 phospho-AKT and serine 136 phospo-bad, p-Erk
(extracellular-regulated signal kinase), and p38 (Cell Sig-
naling Technology, Beverly, MA, USA). The antigen-
antibody complexes were visualized using the lumiglo
chemiluminescent system (Kirkegaard and Perry Labo-
ratories, Gaithersburg, MD, USA).
Statistical analysis
For the apoptosis assays, the data were analyzed using
a Mann-Whitney nonparametric t test. Western blot anal-
ysis demonstrating changes in phosphorylation of AKT
and bad were analyzed using a two-tailed paired t test. In
both cases P < 0.05 was designated as statistically signif-
icant. In all cases error bars represent standard error of
the means (SEM).
RESULTS
Effects of IGF on fetal podocyte apoptosis
To induce apoptosis, we incubated fetal podocytes in
the presence of etoposide. We assayed for apoptosis at
24-hour intervals, up to 96 hours, by examining nuclear
membrane condensation, blebbing, and fragmentation.
Morphologic changes associated with apoptosis were ob-
served as early as 24 hours with a maximum effect at 48,
72, and 96 hours with each time point demonstrating ap-
proximately a threefold increase in apoptosis above con-
trol levels (Fig. 2A). When the media were supplemented
with IGF-1 (200 ng/mL), the number of apoptotic cells
was reduced to control levels at all time points studied.
We did not observe any significant differences between
IGF-1–stimulated cells and control cells (P = 0.34) (N =
4). To confirm these observations, we induced cells to
undergo apoptosis using the conditions described above,
and assayed for DNA fragmentation at 48 hours using a
TUNEL assay. We observed an increase in DNA frag-
mentation in cells induced to undergo apoptosis, while
cells stimulated with IGF-1 did not show an increase in the
number of TUNEL-positive cells (Fig. 2B). These results
indicate that etoposide-induced apoptosis is abrogated by
the addition of IGF-1 in our podocyte cell culture model.
IGF-induced PI3K pathway activation
To demonstrate the involvement of the PI3K/AKT
pathway in the IGF-induced protection from podocyte
apoptosis, we examined the interaction of IRS-1 with the
p85 regulatory subunit of PI3K after stimulation of the
cells with IGF-1. IGF-1 stimulation resulted in the for-
mation of a complex with IRS-1 and the p85 subunit of
PI3K as early as 5 minutes, confirming activation of the
IGF-1R by IGF-1 in our cell culture system (Fig. 3A).
To demonstrate phosphoinositide (PIP) phosphoryla-
tion, an immediate downstream effect of PI3K activa-
tion, we incubated fetal podocytes with radiolabeled 32P,
followed by membrane lipid extractions and thin-layer
chromatography. Our results demonstrated an increase
in PIP2 and PIP3 production at 24 hours, indicating acti-
vation of this pathway with IGF-1 stimulation (Fig. 3B).
Coincubation of the cells with inhibitors of PI3K, Wort-
mannin, and LY294002, abolished IGF-stimulated PIP3
production (Fig. 3B). In addition, incubating the cells with
actinomycin D and cyclohexamide did not affect IGF-
stimulated PIP phosphorylation (Fig. 3B), verifying that
the increase in phosphorylation results directly from IGF
stimulation.
IGF-induced activation of AKT and bad
The AKT protein kinase is linked to the protection
of the cells from apoptosis after growth factor activa-
tion [21]. When cells were induced to undergo apopto-
sis by incubation with etoposide, AKT phosphorylation
decreased, as measured by Western blot analysis. Coin-
cubation of the cells with IGF-1, which rescues cells from
etoposide-induced apoptosis, resulted in an increase in
AKT phosphorylation as compared to etoposide alone,
while coincubation of the cells with etoposide, IGF-1 and
LY294002 resulted in a decrease of AKT phosphoryla-
tion as compared to IGF-1 stimulation in the presence of
etoposide (Fig. 4A).
Members of the bcl-2 gene family have demonstrated
roles in regulating apoptosis and have been shown to
be activated by AKT. One member of this family, bad,
has been shown to inhibit apoptosis in its phosphory-
lated form [11]. In our in vitro cell system, cells induced
to undergo apoptosis with etoposide resulted in a de-
crease in bad phosphorylation. As observed with AKT,
coincubation of the cells with IGF-1 resulted in an in-
crease in bad phosphorylation as compared to etoposide
alone (P = 0.002) (N = 3). As expected, coincubation of
cells with IGF, etoposide, and LY294002 resulted in a de-
crease in bad activation compared to IGF stimulation in
the presence of etoposide, and similar to incubation with
etoposide alone (Fig. 4B). Collectively, these data support
activation of the PI3K pathway and subsequent phospho-
rylation of AKT and bad in the IGF-1–stimulated protec-
tion from apoptosis in our cell system.
IGF-induced activation of mitogen-activated
protein kinase (MAPK)
In other cell systems, stimulation with IGF results in
the activation of p38 MAPK or Erk MAPK. In our sys-
tem, neither p38 nor Erk were activated when cells were
induced to undergo apoptosis in the presence of etopo-
side. In addition, no differences in the phosphorylation
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Fig. 1. Characterization of the podocyte
monolayer. (A) Photomicrograph demon-
strating synaptopodin immunoreactivity in
the podocyte monolayer. See Methods section
for details (magnification ×200). (B) Western
blot analysis of nephrin expression using pro-
tein extracted from cell monolayers after in-
cubation in 1% fetal calf serum for 24, 48, and
72 hours. See Methods section for details.
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Fig. 2. Insulin-like growth factor (IGF)-induced protection from apoptosis. Podocyte cell cultures were induced to undergo apoptosis using etopo-
side (E) and the number of apoptotic cells and total cells were counted in each of five fields as described in the Methods section. (A) Bar graph
depicting the fold change in apoptotic cells in control, etoposide (200 lmol/L), and etoposide + IGF-1 (200 ng/mL)–treated cells as determined by
the morphologic features associated with apoptosis. In the presence of etoposide a two- to threefold increase was observed as early as 24 hours.
∗P = 0.029 vs. control (N = 4). Coincubation with etoposide and IGF-1 reduced apoptosis to control levels. (B) Terminal deoxytransferase (TdT)
uridine triphosphate (UTP) nick end-labeling (TUNEL) assay to detect DNA fragmentation in our cultured podocyte cell model. Green nuclei
represent DNA fragmentation, a biochemical marker for apoptosis. Cells were incubated in control conditions [1% fetal bovine serum (FBS)] or
induced to undergo apoptosis using etoposide in the presence or absence of IGF-1 (200 ng/mL). Error bars = SEM. Symbols are: ←, healthy cells;
, apoptotic cells.
of p38 or Erk were observed under the same conditions
but in the presence of IGF-1 (data not shown).
Podocyte apoptosis with PI3K pathway inhibitors
To confirm a role for the PI3K pathway in protecting
our podocyte cell cultures from apoptosis, we induced
our cells to undergo apoptosis with etoposide in the pres-
ence or absence of IGF-1 and LY294002 for 48 hours. As
expected, incubation with etoposide resulted in an ap-
proximately threefold increase in apoptosis as compared
to the control, while coincubation with IGF-1 resulted in
a 2.5-fold decrease in apoptosis, compared to etoposide
exposed cells (P = 0.029, N = 4). In the presence of PI3K
1312 Bridgewater et al: IGFs inhibit podocyte apoptosis
18,000
15,000
12,000
9000
6000
3000
0PI
P3
 p
ro
du
ct
io
n,
cp
m
Co
ntr
ol
IGF
-1
IGF
-1 
wo
rtm
an
nin
IGF
-1 
Ly2
94
00
2
Cy
clo
he
xim
ide
Ac
tin
om
yci
n D
Treatment
* *
*
B
IP IRS-1
0 5' 10'
85 kD p85
A
Fig. 3. Insulin-like growth factor (IGF)-induced phosphatidylinositol
3′-kinase (PI3K) pathway activation. (A) Total protein was extracted
from cell lysates and immunoprecipitation was performed using the
insulin receptor substrate-1 (IRS-1) antibody. Western blot analysis us-
ing the p85 antibody demonstrated IRS-1-p85 complex formation with
a band at 85 kD as early as 5 minutes after IGF-1 stimulation. (B)
Using thin-layer chromatography, phosphoinositide (PIP) phosphory-
lation and PIP3 production were measured after IGF-1 stimulation (see
Methods section for details), in the presence and absence of the PI3 ki-
nase inhibitors LY294002 (1 lmol/L) and Wortmannin (1 lmol/L), and
inhibitors of DNA and protein synthesis (cycloheximide 20 lmol/L,
and Actinomycin D 1 lmol/L). IGF stimulation resulted in an ap-
proximate threefold increase in PIP3 production, an effect abrogated
by coincubation with PI3K inhibitors, and unaffected by coincubation
with inhibitors of new DNA and protein synthesis. P < 0.05 vs. control
(N = 6).
pathway inhibitors, the protective effect of IGF-1 was
abrogated, and the number of apoptotic cells increased
when compared to incubation in the presence of IGF-1
(Fig. 5). These results confirm that our cultured podocytes
are protected from apoptosis with IGF-1 stimulation, and
that this protective effect is mediated primarily through
the PI3K pathway.
DISCUSSION
In this study we analyzed the role of the IGF system
in regulating podocyte apoptosis. Recent studies have
highlighted the importance of the podocyte in several
renal pathologies [22]. For example, mutations in sev-
eral proteins expressed exclusively in the podocyte, in-
cluding CD2AP [23], nephrin [5], alpha-actinin [4], and
podocin [3] result in progressive renal diseases associated
with podocyte damage. With the recognition of the clini-
cal importance of the podocyte, an understanding of the
growth factors regulating its differentiation, maturation,
maintenance, and survival is beginning to emerge.
IGFs and IGF-1R are expressed in both the devel-
oping and the mature glomerulus [7, 24–26]. The IGFs
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Fig. 4. Insulin-like growth factor (IGF)-induced AKT and bad acti-
vation. Cells were maintained in control conditions [1% fetal bovine
serum (FBS)] (lane 1) or stimulated with etoposide (lane 2), etoposide
+ IGF-1 (200 ng/mL) (lane 3), and etoposide + IGF-1 + LY294002 (1
lmol/L) (lane 4). (A) Western blot analysis and corresponding densit-
ometry demonstrating the changes in AKT phosphorylation. In cells
incubated in the presence of IGF-1 and etoposide, AKT phosphory-
lation was increased compared to etoposide alone (∗P = 0.03) (N =
3), an effect inhibited by coincubation of LY294002 (#P = 0.02) (N =
3). (B) Western blot analysis and corresponding densitometry demon-
strating the changes in bad phosphorylation. In cells incubated in the
presence of IGF-1 and etoposide, bad phosphorylation was increased
compared to etoposide alone (∗P = 0.002) (N = 3), an effect inhibited
by coincubation of LY294002 (#P = 0.005) (N = 3). Error bars represent
SEM.
have demonstrated roles in renal development, and as
cell survival factors [8, 10]. In IGF-1–null mice, the kid-
neys are proportionally smaller and also demonstrate a
decrease in glomerular size and number [31]. In vitro ex-
periments have also demonstrated altered nephrogenesis
when the biologic effects of the IGFs are inhibited [7, 8,
10]. Marked alterations in IGF expression have been ob-
served in various renal diseases, including human multi-
cystic renal disease, lupus glomerulonephritis [27], and in
human examples of kidney disease, including Simpson
Bridgewater et al: IGFs inhibit podocyte apoptosis 1313
4
3
2
1
0
Fo
ld
 in
cr
ea
se
 in
 a
po
pt
os
is
Co
ntr
ol
Ve
hic
le 
co
ntr
ol
(DM
SO
)
Eto
po
sid
e
Eto
po
sid
e +
 
IGF
-1
Eto
po
sid
e +
 
IGF
-1
+ 
LY
29
40
02
*
#
Fig. 5. Podocyte apoptosis in the presence of phosphatidylinositol
3′-kinase (PI3K) inhibitors. Cells were incubated with etoposide in
the presence or absence of IGF-1 (200 ng/mL) and PI3K inhibitor,
LY294002 (1 lmol/L), and assayed for morphologic features of apop-
tosis at 48 hours. A threefold decrease in the number of apoptotic
podocytes was observed when cells were coincubated with etoposide
and IGF-1 as compared to etoposide alone (∗P = 0.029) (N = 4). This
IGF-1–induced protective effect was fully abrogated by coincubation of
cells with LY294002 (#P = 0.029) (N = 4). DMSO is dimethyl sulfoxide.
Golabi Behmel syndrome, Beckwith-Wiedemann syn-
drome [28], Wilm’s tumor [29], and diabetic nephropathy
[30].
We have demonstrated that IGF-1 inhibits apoptosis in
human fetal podocytes when cultured in the presence of
etoposide. Other investigators have demonstrated a sim-
ilar anti-apoptotic role for the IGF-1 in PC12 cells [31],
brown adipocytes [32], and several other cells. However,
in immortalized mouse podocytes, hepatocyte growth fac-
tor protected cells from cyclosporine induced apoptosis,
while IGF did not [33]. The lack of an IGF-1–induced pro-
tective effect on apoptosis in this system is likely due to
the direct effect of cyclosporine on expression of apop-
totic regulatory genes, the final common target of IGF
stimulation.
The antiapoptotic effects of the IGFs appear to be
mediated through engagement of the IGF-1R, which
then activates the PI3K pathway or the MAPK path-
way, as described in other cell models [12, 13, 31, 32].
Our data support a role for the activation of the PI3K
pathway in protecting the human fetal podocyte, in vitro,
from apoptosis. We have shown that the mechanism is
mediated through stimulation of the IGF-1R, and subse-
quent activation and recruitment of downstream signal-
ing molecules, including the p85 subunit of PI3K pathway,
PIP to PIP3 phosphorylation, AKT activation, and phos-
phorylation of bcl-2 family member bad. Previous studies
have demonstrated that AKT/PKB phosphorylation de-
livers an antiapoptotic signal when rescuing cells from
apoptosis induced by various stimuli [11, 13, 21] by regu-
lating bcl-2 family members [11]. Activation of members
of this family, such as bad, has been shown to main-
tain the integrity of the mitochondrial membrane and
prevent caspase activation, thereby preventing apopto-
sis [34]. Our data demonstrate that bad is phosphory-
lated in response to IGF-1 stimulation resulting in an
inhibition of apoptosis in our fetal podocyte cell cul-
tures. The importance of the PI3K pathway to podocyte
survival is supported by the recent finding that nephrin
and CD2AP interact with the p85 regulatory subunit
of PI3K and together with podocin stimulate AKT sig-
naling in podocytes. In addition this study also demon-
strated that bad is a target of AKT signaling in podocytes
and may be involved in protecting podocytes from de-
tachment induced cell death [35]. Although these stud-
ies demonstrate the importance of the PI3K pathway, we
considered the possibility of contribution from other in-
tracellular pathways. In the presence of PI3K inhibitors,
IGF-induced protection from apoptosis was increased to
levels observed with the apoptotic insult alone; suggesting
that this is the primary pathway employed during IGF-
stimulated protection from apoptosis. Furthermore, we
were unable to show any effect of IGF stimulation on
phosphorylation of members of the MAPK pathway, in-
cluding erk and p38 MAPK.
CONCLUSION
IGFs appear to be important factors in maintaining
podocyte survival, particularly in in vitro conditions fa-
voring apoptosis. These results could potentially lead to
interventions that prevent or slow podocyte damage and
therefore the progression to end-stage renal failure. To
that end, work is in progress to confirm these findings in
vivo.
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